{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:24:20Z","timestamp":1793309060456,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"12","funder":[{"name":"The Eye Cancer Foundation"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1136\/bjophthalmol-2017-310315","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:35:18Z","timestamp":1492475718000},"page":"1694-1698","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab"],"prefix":"10.1136","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-4169","authenticated-orcid":false,"given":"Richard I","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal S","family":"Chaugule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2017-310315-1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.1987.03390060070017","article-title":"Radiation retinopathy","volume":"257","author":"Gliedman","year":"1987","journal-title":"JAMA"},{"key":"key-10.1136\/bjophthalmol-2017-310315-2","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0161-6420(82)34611-4","article-title":"Radiation retinopathy","volume":"89","author":"Brown","year":"1982","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2017-310315-3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2008.12.027","article-title":"Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients","volume":"116","author":"Finger","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2017-310315-4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/bjo.2004.052159","article-title":"Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy","volume":"89","author":"Finger","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjo.84.9.1068","article-title":"Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy","volume":"84","author":"Finger","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archophthalmol.2009.376","article-title":"Intravitreous ranibizumab (lucentis) for radiation maculopathy","volume":"128","author":"Finger","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ajo.2009.11.006","article-title":"Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma","volume":"149","author":"Finger","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/eye.1990.93","article-title":"Fluorescein angiographic features, natural course and treatment of radiation retinopathy","volume":"4(Pt 5)","author":"Amoaku","year":"1990","journal-title":"Eye"},{"key":"key-10.1136\/bjophthalmol-2017-310315-9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","author":"American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com","year":"2014","journal-title":"Brachytherapy"},{"key":"key-10.1136\/bjophthalmol-2017-310315-10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/IAE.0b013e31816b3192","article-title":"Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma","volume":"28","author":"Horgan","year":"2008","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2017-310315-11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00006982-200510000-00009","article-title":"Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma","volume":"25","author":"Shields","year":"2005","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2017-310315-12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/archopht.125.6.751","article-title":"Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy","volume":"125","author":"Finger","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-14","first-page":"1739","article-title":"Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity","volume":"6","author":"Shah","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5301\/ejo.5000670","article-title":"Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study","volume":"26","author":"Finger","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/ICB.0000000000000032","article-title":"Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant","volume":"8","author":"Bui","year":"2014","journal-title":"Retin Cases Brief Rep"},{"key":"key-10.1136\/bjophthalmol-2017-310315-17","first-page":"1877","article-title":"Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma","volume":"7","author":"Shah","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5301\/EJO.2014.12778","article-title":"Angled transscleral intravitreal injection: a crossover study","volume":"25","author":"Mehta","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3892\/mco.2014.247","article-title":"Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: a meta-analysis","volume":"2","author":"Yang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/IAE.0b013e3182437e70","article-title":"Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study","volume":"32","author":"Materin","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2017-310315-21","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(98)98023-X","article-title":"The efficacy of focal laser therapy in radiation-induced macular edema","volume":"105","author":"Hykin","year":"1998","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2017-310315-22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1167\/iovs.09-4065","article-title":"Alterations in the intraocular cytokine milieu after intravitreal bevacizumab","volume":"51","author":"Forooghian","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2017-310315-23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2174\/1566524014666140128114414","article-title":"Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema","volume":"14","author":"Zhang","year":"2014","journal-title":"Curr Mol Med"},{"key":"key-10.1136\/bjophthalmol-2017-310315-24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1002196930726","article-title":"Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema","volume":"97","author":"Gillies","year":"1999","journal-title":"Doc Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/IAE.0000000000000109","article-title":"Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab","volume":"34","author":"Jeon","year":"2014","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2017-310315-26","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","article-title":"Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans","volume":"31","author":"Meyer","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2017-310315-27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5301\/ejo.5000333","article-title":"High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy","volume":"23","author":"Finger","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2017-310315-28","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ophtha.2009.02.002","article-title":"Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review","volume":"116","author":"Yilmaz","year":"2009","journal-title":"Ophthalmology"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:08Z","timestamp":1601110508000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,11,23]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310315"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310315","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,17]]}}}